Logo image of GNPX

GENPREX INC (GNPX) Stock Overview

USA - NASDAQ:GNPX - US3724462037 - Common Stock

0.2443 USD
+0.04 (+20.76%)
Last: 10/8/2025, 7:28:13 PM
0.238 USD
-0.01 (-2.58%)
After Hours: 10/8/2025, 7:28:13 PM

GNPX Key Statistics, Chart & Performance

Key Statistics
52 Week High3.97
52 Week Low0.14
Market Cap10.48M
Shares42.91M
Float42.79M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-5.64
PEN/A
Fwd PEN/A
Earnings (Next)11-11 2025-11-11/amc
IPO03-29 2018-03-29
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


GNPX short term performance overview.The bars show the price performance of GNPX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

GNPX long term performance overview.The bars show the price performance of GNPX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of GNPX is 0.2443 USD. In the past month the price decreased by -2.32%. In the past year, price decreased by -29.16%.

GENPREX INC / GNPX Daily stock chart

GNPX Latest News, Press Relases and Analysis

GNPX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.84 408.50B
AMGN AMGEN INC 13.51 158.61B
GILD GILEAD SCIENCES INC 15.28 146.73B
VRTX VERTEX PHARMACEUTICALS INC 24.86 107.98B
REGN REGENERON PHARMACEUTICALS 12.35 59.76B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.08B
ARGX ARGENX SE - ADR 86.19 48.90B
ONC BEONE MEDICINES LTD-ADR 5.67 38.56B
INSM INSMED INC N/A 34.20B
BNTX BIONTECH SE-ADR N/A 25.55B
NTRA NATERA INC N/A 23.62B
BIIB BIOGEN INC 9.43 22.13B

About GNPX

Company Profile

GNPX logo image Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2018-03-29. The firm's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.

Company Info

GENPREX INC

3300 Bee Cave Road, Suite 650-227

Austin TEXAS 78712 US

CEO: J. Rodney Varner

Employees: 15

GNPX Company Website

GNPX Investor Relations

Phone: 18777744679

GENPREX INC / GNPX FAQ

What is the stock price of GENPREX INC today?

The current stock price of GNPX is 0.2443 USD. The price increased by 20.76% in the last trading session.


What is the ticker symbol for GENPREX INC stock?

The exchange symbol of GENPREX INC is GNPX and it is listed on the Nasdaq exchange.


On which exchange is GNPX stock listed?

GNPX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GENPREX INC stock?

7 analysts have analysed GNPX and the average price target is 7.65 USD. This implies a price increase of 3031.4% is expected in the next year compared to the current price of 0.2443. Check the GENPREX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GENPREX INC worth?

GENPREX INC (GNPX) has a market capitalization of 10.48M USD. This makes GNPX a Nano Cap stock.


How many employees does GENPREX INC have?

GENPREX INC (GNPX) currently has 15 employees.


What are the support and resistance levels for GENPREX INC (GNPX) stock?

GENPREX INC (GNPX) has a support level at 0.23 and a resistance level at 0.27. Check the full technical report for a detailed analysis of GNPX support and resistance levels.


Should I buy GENPREX INC (GNPX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GENPREX INC (GNPX) stock pay dividends?

GNPX does not pay a dividend.


When does GENPREX INC (GNPX) report earnings?

GENPREX INC (GNPX) will report earnings on 2025-11-11, after the market close.


What is the Price/Earnings (PE) ratio of GENPREX INC (GNPX)?

GENPREX INC (GNPX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.64).


What is the Short Interest ratio of GENPREX INC (GNPX) stock?

The outstanding short interest for GENPREX INC (GNPX) is 12.37% of its float. Check the ownership tab for more information on the GNPX short interest.


GNPX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to GNPX. When comparing the yearly performance of all stocks, GNPX is a bad performer in the overall market: 89.49% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

GNPX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to GNPX. The financial health of GNPX is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GNPX Financial Highlights

Over the last trailing twelve months GNPX reported a non-GAAP Earnings per Share(EPS) of -5.64. The EPS increased by 70.08% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -518.59%
ROE -1320.11%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%92.95%
Sales Q2Q%N/A
EPS 1Y (TTM)70.08%
Revenue 1Y (TTM)N/A

GNPX Forecast & Estimates

7 analysts have analysed GNPX and the average price target is 7.65 USD. This implies a price increase of 3031.4% is expected in the next year compared to the current price of 0.2443.


Analysts
Analysts82.86
Price Target7.65 (3031.4%)
EPS Next Y85.94%
Revenue Next YearN/A

GNPX Ownership

Ownership
Inst Owners1.74%
Ins Owners0.21%
Short Float %12.37%
Short Ratio0.39